Sanders Statement on Medicare Limiting Coverage for Alzheimer’s Drug

January 18, 2022

Sanders Statement on Medicare Limiting Coverage for Alzheimer’s Drug WASHINGTON –
Sen. Bernie Sanders (I-Vt.) Tuesday issued the following statement after the Centers for Medicare and Medicaid Services (CMS) proposed a rule that would cover Aduhelm, the outrageously expensive Alzheimer’s treatment, and similar drugs in development only for people enrolled in qualifying clinical trials:
“Biogen’s outrageous original price for Aduhelm, $56,000 per year, is the poster child for how dysfunctional our drug pricing system has become and it is the perfect example of why Medicare should be negotiating drug prices with the pharmaceutical industry. If the administration …

Read the source article at commondreams.org
2022-01-12 00:35:12

Share This Story!